{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:01:18Z","timestamp":1793721678448,"version":"4.6.1"},"reference-count":13,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,5,10]],"date-time":"2019-05-10T00:00:00Z","timestamp":1557446400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Ocular Technologies Sarl"}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.ophtha.2019.03.050","type":"journal-article","created":{"date-parts":[[2019,4,6]],"date-time":"2019-04-06T18:17:16Z","timestamp":1554574636000},"page":"1230-1237","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":111,"title":["A Phase 3, Randomized, Double-Masked Study of OTX-101 Ophthalmic Solution 0.09% in the Treatment of Dry Eye Disease"],"prefix":"10.1016","volume":"126","author":[{"given":"Damien F.","family":"Goldberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjan P.","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry A.","family":"Schechter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Justice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7659-8203","authenticated-orcid":false,"given":"Sidney L.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Sheppard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2019.03.050_bib1","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jtos.2017.05.011","article-title":"TFOS DEWS II pathophysiology report","volume":"15","author":"Bron","year":"2017","journal-title":"Ocul Surf"},{"key":"10.1016\/j.ophtha.2019.03.050_bib2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3109\/08830185.2012.748052","article-title":"Dry eye as a mucosal autoimmune disease","volume":"32","author":"Stern","year":"2013","journal-title":"Int Rev Immunol"},{"key":"10.1016\/j.ophtha.2019.03.050_bib3","series-title":"Restasis package insert","year":"2013"},{"key":"10.1016\/j.ophtha.2019.03.050_bib4","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ajo.2003.10.036","article-title":"Antiinflammatory therapy for dry eye","volume":"137","author":"Pflugfelder","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2019.03.050_bib5","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1073\/pnas.89.9.3686","article-title":"Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A","volume":"89","author":"Fruman","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ophtha.2019.03.050_bib6","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0161-6420(99)00176-1","article-title":"Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease","volume":"107","author":"Sall","year":"2000","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2019.03.050_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4155\/tde.12.122","article-title":"Nanomicelles: an emerging platform for drug delivery to the eye","volume":"4","author":"Vadlapudi","year":"2013","journal-title":"Ther Deliv"},{"key":"10.1016\/j.ophtha.2019.03.050_bib8","doi-asserted-by":"crossref","unstructured":"Weiss SL, Kramer WG, Velagaleti P, Gilger B. Ocular distribution of cyclosporine following topical administration of OTX-101 in New Zealand White rabbits. Poster presentation: ARVO; 29 April\u20133 May 2018; Honolulu, Hawaii.","DOI":"10.1089\/jop.2018.0106"},{"key":"10.1016\/j.ophtha.2019.03.050_bib9","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.2147\/OPTH.S175065","article-title":"A\u00a0phase II\/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease","volume":"12","author":"Tauber","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.ophtha.2019.03.050_bib10","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S1542-0124(12)70053-8","article-title":"Development and validation of a short global dry eye symptom index","volume":"5","author":"Schaumberg","year":"2007","journal-title":"Ocul Surf"},{"key":"10.1016\/j.ophtha.2019.03.050_bib11","first-page":"221","article-title":"Report of the National Eye Institute\/Industry Workshop on clinical trials in dry eyes","volume":"21","author":"Lemp","year":"1995","journal-title":"CLAO J"},{"key":"10.1016\/j.ophtha.2019.03.050_bib12","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1001\/archopht.118.11.1489","article-title":"Analysis of topical cyclosporine treatment of patients with dry eye syndrome. Effect on conjunctival lymphocytes","volume":"118","author":"Kunert","year":"2000","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2019.03.050_bib13","doi-asserted-by":"crossref","first-page":"4753","DOI":"10.1167\/iovs.03-0270","article-title":"The relationship between habitual patient-reported symptoms and clinical signs among patients with dry eye of varying severity","volume":"44","author":"Begley","year":"2003","journal-title":"Invest Opthalmol Vis Sci"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642018313228?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642018313228?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T14:06:59Z","timestamp":1758982019000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642018313228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":13,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S0161642018313228"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2019.03.050","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase 3, Randomized, Double-Masked Study of OTX-101 Ophthalmic Solution 0.09% in the Treatment of Dry Eye Disease","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2019.03.050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the American Academy of OphthalmologyThis is an open access article under the CC BY-NC-ND license (<inter-ref xlink: href=http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/>http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/<\/inter-ref>).","name":"copyright","label":"Copyright"}]}}